title: Survival after secondary cytoreduction for recurrent ovarian cancer: which are the prognostic factors?
abstract: OBJECTIVE
  Significant controversy exists concerning the factors affecting survival after secondary cytoreduction (SCR) in recurrent ovarian cancer. This study aims to identify factors independently associated with survival after SCR.
  
  
  METHODS
  We retrospectively retrieved 39 patients with recurrent ovarian cancer. All patients had been initially treated with primary cytoreduction in our institution and received platinum- and paclitaxel-based chemotherapy postoperatively. Disease-free interval (DFI) had to be longer than 6 months. A variety of clinicopathological factors were recorded. Multivariable Cox regression was performed to examine the associations of parameters with survival.
  
  
  RESULTS
  Median survival was equal to 24 months, the median DFI was 22 months, and complete SCR had been achieved in 19/39 patients (48.7%, 95% CI: 32.4-65.2%). Higher number of recurrence sites, clear-cell histological type, and more advanced FIGO stage were independently associated with shorter survival; longer DFI was associated with longer survival. Noticeably, complete SCR lost its significance at the multivariable model, although it was associated with longer survival at the univariable analysis.
  
  
  CONCLUSIONS
  Four factors seem capable of independently modifying survival after SCR: number of recurrence sites, DFI, FIGO stage, and clear cell histology. The two latter factors might reflect aggressive clinicopathological features of the tumor with long-term effect.
authors: First Department of Obstetrics and Gynecology, University of Athens, Athens, Greece. giannisbil@hotmail.com
authors: Ioannis
authors: I
authors: Biliatis
authors: Dimitrios
authors: D
authors: Haidopoulos
authors: Alexandros
authors: A
authors: Rodolakis
authors: Georgios
authors: G
authors: Vlachos
authors: Athanasios
authors: A
authors: Protopapas
authors: Nikolaos
authors: N
authors: Thomakos
authors: Theodoros
authors: T
authors: Sergentanis
authors: Nikolaos
authors: N
authors: Akrivos
authors: Aris
authors: A
authors: Antsaklis
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome